Methotrexate in the Treatment of Advanced Knee Osteoarthritis With Effusion-synovitis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Zhujiang Hospital
- Trial code
- NCT03815448
- Record updated
- 28 February 2024
- Original description
This multicentre randomized placebo-controlled clinical trial aims to evaluate whether methotrexate (MTX) has effects of relieving symptoms and reducing inflammation on advanced knee osteoarthritis (OA) with inflammatory phenotype. Participants will be randomly allocated to either MTX group or placebo group receiving MTX or placebo once a week. The primary outcomes are effusion-synovitis volume measured by magnetic resonance imaging (MRI) and knee pain assessed by visual analogue scale (VAS).Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Methotrexate (MTX) in the Treatment of Advanced Knee Osteoarthritis With Effusion-synovitis
This multicentre randomized placebo-controlled clinical trial aims to evaluate whether methotrexate (MTX) has effects of relieving symptoms and reducing inflammation on advanced knee osteoarthritis (OA) with inflammatory phenotype. Participants will be randomly allocated to either MTX group or placebo group receiving MTX or placebo once a week. The primary outcomes are effusion-synovitis volume measured by magnetic resonance imaging (MRI) and knee pain assessed by visual analogue scale (VAS).
Inclusion: Meet the America College of Rheumatology (ACR) criteria for clinical knee OA assessed by a rheumatologist; Knee pain, visual analogue scale (VAS) pain at least 40mm; Kellgren-Lawrence(K-L) grade of 2-4; Physical examination showed signs of inflammation (at least 2 of the following 4 clinical signs of inflammation: warmth around the joint; tenderness around joint margin; articular cavity effusion; swelling of soft tissue around the knee joint); MRI evaluated effusion synovitis grade of ≥ 2; Capable of understanding the study requirements and willing to cooperate with study instructions, and voluntarily sign informed consent.
Exclusion: Knee surgery or arthroscopic examinations were performed or planned within one year, Severe valgus knee deformity (angle of genu valgum > 30°) or previous traumatic history; Infectious history such as HIV infection; Hypersensitivity to methotrexate; Clinical significant conditions, such as (but not limited to) active malignant tumor, abnormal renal function (assessed by GFR), hepatic abnormalities [active hepatitis B, hepatitis C, abnormal liver function (ALT is more than twice the upper limit)], respiratory diseases (lung infection, pulmonary fibrosis), hematological changes (e.g white blood cell (WBC) count < 4 x 10\^9 /L, platelet < 100 x 10\^9 /L or hemoglobin < 100 g/L), serious diseases of gastrointestinal, endocrine, heart, nerve or brain assessed by clinical physicians; Inflammatory arthritis (such as gout, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, seronegative spondyloarthropathy), systemic lupus erythematosus; MRI contraindications; Intra-articular injection, intramuscular injection or oral glucocorticoid were used within the last 4 weeks; Other anti-synovitis agents (such as hydroxychloroquine and sulfasalazine) were applied in the past 3 months; Pregnant and Lactating women.